Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients

NCT05479045 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT05479045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05479045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Lead sponsor
Georgetown University
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2026
Completion date
November 30, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer stage 3, ovarian cancer stage iii, ovarian cancer stage iv